Xeris Biopharma Holdings (XERS) Accumulated Expenses (2020 - 2026)

Xeris Biopharma Holdings (XERS) has 7 years of Accumulated Expenses data on file, last reported at $32.3 million in Q1 2026.

• Quarterly Accumulated Expenses rose 61.03% year-over-year to $32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.3 million (up 61.03% YoY) and the FY2025 annual result came in at $33.2 million, up 19.62% from the prior year.
• Accumulated Expenses fell to $32.3 million in Q1 2026, from $33.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $37.7 million in Q3 2022 to a low of $19.1 million in Q3 2023.
• A 5-year average of $27.4 million and a median of $25.0 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 64.25% — and 2023, when it plunged 49.42%.
• Tracing XERS's Accumulated Expenses over 5 years: stood at $36.8 million in 2022, then tumbled by 36.09% to $23.5 million in 2023, then rose by 17.89% to $27.7 million in 2024, then increased by 19.62% to $33.2 million in 2025, then dropped by 2.62% to $32.3 million in 2026.
• The last three Accumulated Expenses figures came in at $32.3 million (Q1 2026), $33.2 million (Q4 2025), and $30.4 million (Q3 2025), per Business Quant data.